Gleiss Lutz has provided extensive advice to curasan AG, Kleinostheim (“curasan”) on restructuring. curasan’s shares are admitted to trading on the Frankfurt Stock Exchange’s regulated market.
In addition to new appointments to the management board and supervisory board, the restructuring includes various capital increases. Most recently, these have included a successful increase of the company’s share capital to EUR 9,065,873 while maintaining shareholders’ subscription rights, as resolved upon by the company’s annual general meeting. Before this rights offering was made, the company’s share capital was reduced by EUR 12,254,892 to EUR 6,127,446, merging shares at a ratio of three to one, in order to cover losses. Gleiss Lutz also advised curasan on this measure.
curasan develops, produces and markets biomaterials and other medical devices in the area of bone and tissue regeneration.
The rights offering was a further step in a series of measures to restructure curasan. In the framework of this restructuring, Gleiss Lutz previously advised curasan on two 10% capital increases through private placement of shares with institutional investors in 2018, on issuing a convertible bond with an offer of subscription in Spring 2019, and on two extraordinary shareholders’ meetings in Autumn 2018 and Spring 2019 to resolve upon capital increases.
Gleiss Lutz has been regularly advising curasan on corporate and capital markets law for many years.
curasan was advised by the following team of Gleiss Lutz lawyers: Dr. Stephan Aubel (lead), Dr. Detlef Bauer (both partners, corporate and capital markets, Frankfurt), Dr. Doris-Maria Schuster (partner, employment, Frankfurt/Hamburg), Dr Matthias Tresselt (partner, restructuring, Stuttgart), Alexander Gebhardt, Jan-Rasmus Roßkamp, Dr. Walter Andert and Jannik Hermes (all corporate and capital markets, Frankfurt).
Forward
